Integrated DNA Technologies Inc. Products & Reviews

VariantPlex Expanded Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and MSI from 76 genes associated with various solid tumor malignancies.

VariantPlex Pan Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, MSI, and TMB from 185 genes associated with various solid tumor malignancies.

VariantPlex Complete Solid Tumor is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, MSI, and TMB from 430 genes associated with various solid tumor malignancies.

Immunoverse is a research assay that characterizes the immune repertoire, including assessment of T- and B-cell clonalities and rare clones, and detection of tumor infiltrating lymphocytes (TIL) and somatic hypermutation with targeted NGS of key T cell receptor and B cell receptor chain RNA relevant for blood cancer and solid tumor research.

VariantPlex Myeloid is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and ITDs from 75 genes associated with acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS).

VariantPlex Core Myeloid is a research assay for targeted next generation sequencing of DNA for characterization of SNVs, indels, CNVs, and ITDs from 37 genes associated with acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS).

FusionPlex Pan Heme is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 199 genes associated with lymphoid and myeloid malignancies.

FusionPlex Heme V2 is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 87 genes associated with lymphoid and myeloid malignancies.

FusionPlex Myeloid is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 84 genes associated with myeloid-origin malignancies.

FusionPlex Lymphoma is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 125 genes associated with lymphomas.

FusionPlex ALL is a research assay for targeted next generation sequencing of RNA for characterization of variants, indels, expression, and fusions, including novel fusions, from 81 genes associated with acute lymphoblastic leukemia (ALL) .

Ideal for small scale in vitro applications, screening DsiRNA duplex pricing includes affinity purification.

Trifectin is a proprietary cationic lipid formulation that has been optimized for delivery of IDT’s Dicer-Substrate siRNAs into a wide variety of cell types with minimal toxicity.